532 related articles for article (PubMed ID: 28376831)
1. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
[TBL] [Abstract][Full Text] [Related]
2. Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.
Xiao M; Guo J; Xie L; Yang C; Gong L; Wang Z; Cai J
Mol Cancer Res; 2020 Mar; 18(3):436-447. PubMed ID: 31722968
[TBL] [Abstract][Full Text] [Related]
3. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
6. A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance.
Ceccaldi R; O'Connor KW; Mouw KW; Li AY; Matulonis UA; D'Andrea AD; Konstantinopoulos PA
Cancer Res; 2015 Feb; 75(4):628-34. PubMed ID: 25634215
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
8. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer.
Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N
Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762
[TBL] [Abstract][Full Text] [Related]
9. Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
Long J; Zhu JY; Liu YB; Fu K; Tian Y; Li PY; Yang WQ; Yang SY; Yin JY; Yin G; Zhang Y
Gynecol Oncol; 2018 May; 149(2):341-349. PubMed ID: 29572031
[TBL] [Abstract][Full Text] [Related]
10. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
11. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1.
Wang Y; Bao W; Liu Y; Wang S; Xu S; Li X; Li Y; Wu S
Cell Death Dis; 2018 May; 9(5):447. PubMed ID: 29670086
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer.
Biamonte F; Santamaria G; Sacco A; Perrone FM; Di Cello A; Battaglia AM; Salatino A; Di Vito A; Aversa I; Venturella R; Zullo F; Costanzo F
Sci Rep; 2019 Apr; 9(1):5668. PubMed ID: 30952937
[TBL] [Abstract][Full Text] [Related]
13. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
14. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
15. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
[No Abstract] [Full Text] [Related]
16. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
[TBL] [Abstract][Full Text] [Related]
17. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
18. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
19. [Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
Shi L; Yu H; Zhang W; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):523-30. PubMed ID: 25327735
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
